Most nmCRPC Patients Can Safely Take Full Dose of Nubeqa, Trial Analysis Shows

Most nmCRPC Patients Can Safely Take Full Dose of Nubeqa, Trial Analysis Shows
Nearly all men with non-metastatic castration-resistant prostate cancer (nmCRPC) received the full planned dose of Nubeqa (darolutamide) tablets while participating in the ARAMIS Phase 3 trial, and few required dose adjustments or discontinued treatment, according to a new ad-hoc analysis of the study. Findings from this analysis were recently presented in an e-poster, titled "Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial," at the ESMO Virtual Congress 2020, held online Sept. 19–21. Nubeqa, jointly developed by Bayer and Orion, is an oral medication approved for men with nmCRPC. The medication works by inhibiting androgen receptors — proteins found on the surface of cells that bind to male hormones — and
Subscribe or to access all post and page content.